Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Unresectable Urothelial Carcinoma: early-phase trial registry
4 of 6 indexed Unresectable Urothelial Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 4 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Unresectable Urothelial Carcinoma: 6 US clinical trials tracked, 4 recruiting.
Unresectable Urothelial Carcinoma is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition unresectable-urothelial-carcinoma
OPEN 4 | RECR 67% | LATE 1 | EARLY 5 | RANK #2866 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Adenocarcinoma of Lung (67% recruiting · 6 trials)
Unresectable Urothelial Carcinoma lists 4 open slots (67% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Unresectable Urothelial Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Unresectable Urothelial Carcinoma is recruiting above its size-band peers.
4 of 6 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Unresectable Urothelial Carcinoma research.
National Cancer Institute (NCI) accounts for 3 of 6 trials (50%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Unresectable Urothelial Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 97 among the 6 trials that report a genuine target (sentinel values excluded). 4 of those (66.7%) plan for fewer than 100 participants.
-
Unresectable Urothelial Carcinoma research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
National Cancer Institute (NCI)
NCT06524544
Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma
Fox Chase Cancer Center
NCT07221942
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Emory University
NCT04878029
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
National Cancer Institute (NCI)
NCT06439836
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
National Cancer Institute (NCI)
NCT00365157
Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma
University of Utah
NCT05154994
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Unresectable Urothelial Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Unresectable Urothelial Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Unresectable Urothelial Carcinoma page
6 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Unresectable Urothelial Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Unresectable Urothelial Carcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Unresectable Urothelial Carcinoma condition card totals 6 registered trials; most-linked intervention Computed Tomography; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.